[
    {
        "pregunta": "1. What are the first-line treatment options recommended for patients with active, nonsevere eosinophilic granulomatosis with polyangiitis (EGPA)?",
        "respuesta": "For patients with active, nonsevere eosinophilic granulomatosis with polyangiitis (EGPA), the first-line treatment options recommended are glucocorticoids combined with either mepolizumab or one of the following immunosuppressive agents: methotrexate, azathioprine, or mycophenolate mofetil. Specifically, initiating treatment with mepolizumab plus glucocorticoids is conditionally recommended over methotrexate, azathioprine, or mycophenolate mofetil with glucocorticoids. Adjunctive use of methotrexate, azathioprine, or mycophenolate mofetil alongside glucocorticoids is preferred over glucocorticoids alone to reduce glucocorticoid toxicity.",
        "contexto": [
            "<h1>Key recommendations for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA)</h1>",
            "with active, nonsevere EGPA, we conditionally recommend initiating treatment with mepolizumab and glucocorticoids over methotrexate, azathioprine, or mycophenolate mofetil and glucocorticoids. A range of immunosuppressive agents may be considered in the treatment of active, nonsevere EGPA, all of which are used with glucocorticoids. The clinical profile of nonsevere EGPA includes predominantly asthma, sinus disease, and nonsevere vasculitis. While there is significant clinical experience with",
            "position statement: For patients with active, severe EGPA, either IV pulse glucocorticoids or high-dose oral glucocorticoids may be prescribed as initial therapy. There are no data to support favoring either IV pulse or highdose oral glucocorticoids over the other option in active, severe EGPA. Choosing an approach should be influenced by individual patient factors. In either instance, glucocorticoids should be combined with a nonglucocorticoid immunosuppressive agent such as cyclophosphamide",
            "choice, because it has been found to be efficacious for nonsevere EGPA in a randomized trial Recommendation: For patients with active, nonsevere EGPA, we conditionally recommend initiating treatment with methotrexate, azathioprine, or mycophenolate mofetil and glucocorticoids over glucocorticoids alone. Patients should be treated with adjunctive methotrexate, azathioprine, or mycophenolate mofetil rather than glucocorticoids alone in order to minimize glucocorticoid toxicity. One randomized",
            "severity. The recommendations presented here focus primarily on the use of immunosuppressive medications to treat the vasculitic manifestations of EGPA. However, asthma and allergic manifestations are a significant component of EGPA, and measures directed toward these, including inhaled therapies and allergen avoidance, play an important role in management. Collaboration between rheumatologists, asthma/allergy specialists, and specialists in other medical disciplines can enhance the care of"
        ]
    },
    {
        "pregunta": "2. What are the challenges mentioned regarding the optimal duration of therapy in AAV management?",
        "respuesta": "The challenges regarding the optimal duration of therapy in the management of ANCA-associated vasculitis (AAV) include a lack of definitive evidence or consensus on how long treatment should be continued. Despite randomized clinical trials supporting initial remission induction and maintenance therapy, critical questions remain unanswered about the optimal therapy duration. This gap highlights the need for ongoing research to determine the best length of treatment to balance efficacy and toxicity.",
        "contexto": [
            "2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis  unknown      A7FDDF976624E2E85584FDD8C00804F0 10.1002/acr.24634  INTRODUCTION The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) comprise granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). These diseases affect smalland medium-sized vessels",
            "disease may not be able to receive conventional immunosuppressive therapy (e.g., sepsis or pregnancy), IVIG can be used as a short-term intervention until conventional remission induction therapies can be used Ungraded position statement: The optimal duration of anticoagulation is unknown for patients with GPA/MPA who experience venous thrombotic events. AAV is associated with an increased risk of venous thrombotic events, including both deep vein thromboses and pulmonary emboli Recommendations",
            "minimal toxicity that can accurately assess disease activity and predict outcomes. In addition, while we have evidence from randomized clinical trials to support recommendations regarding initial remission induction and maintenance therapy, critical questions remain unanswered, such as the optimal duration of therapy. These gaps in knowledge reinforce the need for ongoing research in these diseases. Specific areas to investigate include the following: 1) biomarker studies to identify more",
            "<h2>| |Ungraded position statement: The optimal duration of anticoagulation is unknown for patients with GPA/MPA who experience venous thrombotic events.|Very low|</h2>\n\n<h1>Key recommendations for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)</h1>",
            "populations has been estimated to range from 2 to 38 cases per million Prior to the use of alkylating agents, survival with these diseases was quite poor (e.g., median survival of patients with GPA was ~5 months) The Voting Panel was assembled for the ACR and Vasculitis Foundation's broad effort to develop recommendations for 7 forms of systemic vasculitis: giant cell arteritis, Takayasu arteritis, polyarteritis nodosa, Kawasaki syndrome, and the 3 AAVs presented in this report. The physicians"
        ]
    },
    {
        "pregunta": "3. In remission maintenance for severe GPA/MPA, how does rituximab compare to methotrexate or azathioprine?",
        "respuesta": "In remission maintenance for severe GPA or MPA after induction with cyclophosphamide or rituximab, rituximab is conditionally recommended over methotrexate or azathioprine. This recommendation is based on evidence that rituximab is associated with a lower relapse rate compared to azathioprine. Methotrexate and azathioprine are considered equally effective for remission maintenance but are preferred over mycophenolate mofetil and leflunomide.",
        "contexto": [
            "|Remission maintenance| | |\n|Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally recommend treatment with rituximab over methotrexate or azathioprine for remission maintenance.|15, 16, 17, 18|Very low to moderate|",
            "|Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally recommend treatment with methotrexate or azathioprine over mycophenolate mofetil for remission maintenance.|19|Very low to moderate|",
            "and glucocorticoids. Methotrexate is considered more effective than trimethoprim/sulfamethoxazole for remission induction, based on previous findings Remission maintenance Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally recommend treatment with rituximab over methotrexate or azathioprine for remission maintenance. Rituximab is associated with a lower relapse rate than azathioprine when used",
            "ANCA titers had similar rates of relapse as those receiving rituximab as a scheduled dose. However, this study was limited by the small sample size, and there were wide CIs for the effect size Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally rec ommend treatment with methotrexate or azathioprine over mycophenolate mofetil for remission maintenance. Methotrexate and azathioprine are equally",
            "for remission maintenance. Methotrexate and azathioprine are equally efficacious for remission maintenance Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally recommend treatment with methotrexate or azathioprine over leflunomide for remission maintenance. Methotrexate or azathioprine treatment is recommended over leflunomide due to the data supporting and clinical experience using methotrexate"
        ]
    },
    {
        "pregunta": "4. What are the current gaps in knowledge identified by the guideline regarding the treatment of AAV?",
        "respuesta": "The current gaps in knowledge identified by the 2021 ACR/Vasculitis Foundation guideline regarding the treatment of ANCA-associated vasculitis (AAV) include:\n\n- Lack of reliable biomarkers or noninvasive diagnostic tests that can accurately assess disease activity and predict relapse.\n- Insufficient comparative effectiveness and safety data on different biologic therapies.\n- Uncertainty about the optimal sequencing of treatments.\n- Limited evidence on the role and place of NSAIDs in AAV management.\n- Unclear optimal duration of therapy, including maintenance treatment length.\n- Absence of definite guidance on the duration of anticoagulation in patients with GPA/MPA who develop venous thrombotic events.\n\nThese gaps highlight the need for further research to improve personalized and evidence-based treatment approaches in AAV.",
        "contexto": [
            "2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis  unknown      A7FDDF976624E2E85584FDD8C00804F0 10.1002/acr.24634  INTRODUCTION The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) comprise granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). These diseases affect smalland medium-sized vessels",
            "subspecialists may favor a different management strategy. We encourage rheumatologists to discuss treatment plans and coordinate care with other subspecialists as needed. Recently, a clinical trial of avacopan in patients with GPA and MPA was published This guideline highlights gaps in our knowledge for the treatment of AAV. Most glaring is the lack of biomarker assessments or other noninvasive diagnostic testing with minimal toxicity that can accurately assess disease activity and predict",
            "available, this problem will grow. Importantly, failure to recommend a particular medication does not imply that it is contraindicated. Key evidence gaps include the comparative effectiveness and safety of different biologics, the optimal sequencing of treatments, and the role of NSAIDs. This update addressed only a subset of treatment questions. The 2015 recommendations that were not reexamined are to be considered extant. Recommendations are meant to describe the approach to treatment of the",
            "populations has been estimated to range from 2 to 38 cases per million Prior to the use of alkylating agents, survival with these diseases was quite poor (e.g., median survival of patients with GPA was ~5 months) The Voting Panel was assembled for the ACR and Vasculitis Foundation's broad effort to develop recommendations for 7 forms of systemic vasculitis: giant cell arteritis, Takayasu arteritis, polyarteritis nodosa, Kawasaki syndrome, and the 3 AAVs presented in this report. The physicians",
            "disease may not be able to receive conventional immunosuppressive therapy (e.g., sepsis or pregnancy), IVIG can be used as a short-term intervention until conventional remission induction therapies can be used Ungraded position statement: The optimal duration of anticoagulation is unknown for patients with GPA/MPA who experience venous thrombotic events. AAV is associated with an increased risk of venous thrombotic events, including both deep vein thromboses and pulmonary emboli Recommendations"
        ]
    },
    {
        "pregunta": "5. Under what clinical circumstances is plasma exchange not routinely recommended as part of remission induction therapy in GPA/MPA?",
        "respuesta": "Plasma exchange is **not routinely recommended** as part of remission induction therapy in patients with GPA or MPA who have:\n\n- Active glomerulonephritis (conditional recommendation against routine use)\n- Active, severe disease with alveolar hemorrhage (conditional recommendation against addition of plasma exchange)\n\nHowever, plasma exchange may still be considered in patients at higher risk of progression to end-stage renal disease (ESRD) or in those with GPA or MPA who also have anti-glomerular basement membrane disease.",
        "contexto": [
            "|Recommendation: In patients with GPA/MPA with active glomerulonephritis, we conditionally recommend against the routine addition of plasma exchange to remission induction therapy.|34|Low to high|\n|Recommendation: In patients with active, severe GPA/MPA with alveolar hemorrhage, we conditionally recommend against adding plasma exchange to remission induction therapies.|35|Low to high|",
            "venous thrombotic events.  Plasma exchange remains advisable in patients with GPA or MPA who also have anti-glomerular basement membrane disease. Recommendation: In patients with active, severe GPA/MPA with alveolar hemorrhage, we conditionally recommend against adding plasma exchange to remission induction therapies. Two trials evaluated the use of plasma exchange in patients presenting with alveolar hemorrhage, and no differences in mortality or remission rates were observed. Thus, plasma",
            "induction therapies (i.e., plasma exchange as \"salvage\" or \"rescue\" therapy). Plasma exchange remains advisable in patients with GPA or MPA who also have anti-glomerular basement membrane disease. Ungraded position statement: For patients with active, severe GPA/MPA, either IV pulse glucocorticoids or high-dose oral glucocorticoids may be prescribed as part of initial therapy. There are no trials comparing the efficacy of IV pulse glucocorticoids to high-dose oral glucocorticoids. Higher doses",
            "cyclophosphamide for remission induction in a randomized controlled trial Cyclophosphamide (dosing provided in Table 1 Recommendation: In patients with GPA/MPA with active glomerulonephritis, we conditionally recommend against the routine addition of plasma exchange to remission induction therapy. Plasma exchange should not be initiated in all patients with active glomerulonephritis but can be considered for patients at higher risk of progression to end-stage renal disease (ESRD) who accept a",
            "For patients with GPA/MPA in remission and stage 5 chronic kidney disease, we conditionally recommend evaluation for renal transplantation. Low Recommendation: For patients with active GPA/MPA who are unable to receive other immunomodulatory therapy, we conditionally recommend administering IVIG. Low Ungraded position statement: The optimal duration of anticoagulation is unknown for patients with GPA/MPA who experience venous thrombotic events.  Plasma exchange remains advisable in patients"
        ]
    },
    {
        "pregunta": "6. What is the recommended dosing regimen for intravenous pulse glucocorticoids (GCs) used in remission induction therapy for AAV?",
        "respuesta": "The recommended dosing regimen for intravenous pulse glucocorticoids in remission induction therapy for ANCA-associated vasculitis (AAV) is 250–1000 mg methylprednisolone daily for 1 to 3 days, followed by oral glucocorticoids at a dose of ≤0.5 mg/kg/day (maximum 40 mg/day) with a taper to a target dose of ≤5 mg/day by 6 months.",
        "contexto": [
            "we conditionally recommend the addition of RAAS-I. …We conditionally recommend pulse intravenous glucocorticoids 250-1000 mg methylprednisolone daily x 1-3 days, followed by oral glucocorticoid ≤0.5 mg/kg/day (maximum dose 40 mg/day) with taper to a target dose of ≤5mg/day by 6 months. … Who have achieved/sustained a complete renal response after treatment with any (triple or dual) immunosuppressive therapy, we conditionally recommend a total duration of therapy of at least 3-5 years. IN PEOPLE",
            "IV pulse glucocorticoids to high-dose oral glucocorticoids. Higher doses of glucocorticoids (such as pulse glucocorticoids) are generally administered to patients with organ-or life-threatening disease manifestations but may be associated with an increased risk of infection Recommendation: For patients with active, severe GPA/MPA, we conditionally recommend a reduced-dose glucocorticoid regimen over a standard-dose glucocorticoid regimen for remission induction. A recent study demonstrated that",
            "recommend a total duration of therapy of at least 3-5 years. IN PEOPLE WITH ACTIVE IN PEOPLE WITH ACTIVE/NEW ONSET/FLARE OF PURE CLASS V: …With proteinuria ≥1 g/g we conditionally recommend treatment with a TRIPLE immunosuppressive regimen consisting of pulse intravenous glucocorticoids 250-1000 mg methylprednisolone daily x 1-3 days, followed by oral glucocorticoid ≤0.5 mg/kg/day (maximum dose 40 mg/day) with taper and MPAA plus CNI. … With proteinuria <1 g/g, we conditionally recommend",
            "regimen for remission induction. A recent study demonstrated that a reduced-dose glucocorticoid regimen provided a similar benefit compared to a standarddose regimen for the composite outcome of ESRD or death, and was associated with a decreased risk of infection http://onlin e libr ary.wiley.com/doi/10.1002/acr.24634/ abstract Remission induction for active, nonsevere disease Recommendation: For patients with active, nonsevere GPA, we conditionally recommend initiating treatment with",
            "followed by 0.6 mg an hour later, with ongoing antiinflammatory therapy until the flare resolves). Based on similar efficacy between agents demonstrated in the NMA , the Voting Panel did not further prioritize between the first-line agents, noting that treatment selection should be driven by patient factors (e.g., comorbidity, access, past experience) as part of shared decisionmaking. Likewise, parenteral glucocorticoids were favored over alternative agents when oral dosing is not possible. In"
        ]
    },
    {
        "pregunta": "7. What role do rituximab and cyclophosphamide play in remission induction for GPA and MPA, and which is preferred?",
        "respuesta": "For remission induction therapy in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) with active, severe disease, rituximab is conditionally recommended over cyclophosphamide. Both rituximab and cyclophosphamide, combined with glucocorticoids, have demonstrated similar efficacy for remission induction in these conditions.\n\nIn cases of relapse with severe disease manifestations occurring during rituximab maintenance therapy, switching from rituximab to cyclophosphamide for remission re-induction is conditionally recommended over administering additional rituximab.\n\nFor refractory severe GPA/MPA not responding to either rituximab or cyclophosphamide, switching to the alternate agent is conditionally recommended instead of combining the two.\n\nThus, rituximab is preferred as first-line remission induction treatment for severe GPA/MPA, with cyclophosphamide as an alternative or subsequent option based on clinical context such as prior treatment history.",
        "contexto": [
            "abstract Table 1 2 1 Remission induction for active, severe disease Recommendation: For patients with active, severe GPA/MPA, we conditionally recommend treatment with rituximab over cyclophosphamide for remission induction. Both rituximab and cyclophosphamide, in combination with glucocorticoids, have been used for remission induction in GPA and MPA. Rituximab has been shown to provide similar benefits to cyclophosphamide for remission induction in a randomized controlled trial",
            "randomized controlled trial Recommendation: For patients with GPA/MPA who experienced relapse with severe disease manifestations while receiving rituximab for remission maintenance, we conditionally recommend switching from rituximab to cyclophosphamide over receiving additional rituximab for remission re-induction. Multiple factors can influence whether rituximab or cyclophosphamide treatment (IV or oral) is used, such as time since last rituximab infusion and cumulative cyclophosphamide dose.",
            "|Recommendation: For patients with GPA/MPA who experienced relapse with severe disease manifestations while receiving rituximab for remission maintenance, we conditionally recommend switching from rituximab to cyclophosphamide over receiving additional rituximab for remission re-induction.|29|Very low|\n|Treatment of refractory disease| | |",
            "|Treatment of refractory disease| | |\n|Recommendation: For patients with severe GPA/MPA that is refractory to treatment with rituximab or cyclophosphamide for remission induction, we conditionally recommend switching treatment to the other therapy over combining the 2 therapies.|30|Very low|</p>",
            "time since last rituximab infusion and cumulative cyclophosphamide dose. Cyclophosphamide is recommended if the patient recently received rituximab, while a remission induction dose of rituximab may be | 1097 effective if an extended period has passed since the last rituximab infusion. As is standard for remission induction, these agents should be used in conjunction with glucocorticoids. Treatment of refractory disease Recommendation: For patients with severe GPA/MPA that is refractory to"
        ]
    },
    {
        "pregunta": "8. Why is prophylaxis against Pneumocystis jirovecii pneumonia recommended in EGPA patients receiving cyclophosphamide or rituximab?",
        "respuesta": "Prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is conditionally recommended for patients with eosinophilic granulomatosis with polyangiitis (EGPA) who are receiving cyclophosphamide or rituximab because these immunosuppressive therapies increase the risk of opportunistic infections, including PJP. This recommendation aligns with similar guidance for patients with GPA or MPA on these agents, reflecting the need to prevent this potentially severe infection during treatment with potent immunosuppressants.",
        "contexto": [
            "|Recommendation: For patients with EGPA who are receiving cyclophosphamide or rituximab, we conditionally recommend prescribing medications for prophylaxis to prevent Pneumocystis jiroveci pneumonia.|32|Low|</p>",
            "recommend against dosing immunosuppressive therapy based on ANCA titer results alone. Increases in ANCA titers/levels are only modestly informative as an indicator of disease activity Recommendation: For patients with GPA/MPA who are receiving rituximab or cyclophosphamide, we conditionally recommend prophy laxis to prevent P jirovecii pneumonia. Prophylaxis to prevent P jirovecii pneumonia is routinely used with cyclophosphamide treatment Very low Recommendation: For patients with EGPA, we",
            "| |Recommendation: For patients with GPA who are receiving rituximab or cyclophosphamide, we conditionally recommend prophylaxis to prevent Pneumocystis jiroveci pneumonia.|Low|\n| |Recommendation: For patients with GPA/MPA in remission and stage 5 chronic kidney disease, we conditionally recommend evaluation for renal transplantation.|Low|",
            "recommend prescribing medications for prophylaxis to prevent P jirovecii pneumonia. Prophylaxis to prevent P jirovecii pneumonia is discussed above in the GPA/MPA recommendations. The same considerations regarding prophylaxis to prevent this condition in patients with GPA/MPA apply to those with EGPA. DISCUSSION In this guideline, we present the first ACR/Vasculitis Foundation recommendations for the management of GPA, MPA, and EGPA. Although these recommendations provide a general guide for",
            "1103 therapies in EGPA is not well established, some patients may benefit. Where possible, consultation with an otolaryngologist with expertise in treating AAV should be obtained to guide the use and choice of these agents. These interventions can continue to be beneficial even when symptoms have improved or resolved. Recommendation: For patients with EGPA who are receiving cyclophosphamide or rituximab, we conditionally recommend prescribing medications for prophylaxis to prevent P jirovecii"
        ]
    },
    {
        "pregunta": "9. What is the recommendation regarding the use of trimethoprim/sulfamethoxazole for remission maintenance in GPA/MPA?",
        "respuesta": "For remission maintenance in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), the guidelines **conditionally recommend against adding trimethoprim/sulfamethoxazole (TMP/SMX) to other therapies** such as rituximab, azathioprine, or methotrexate. Instead, methotrexate or azathioprine is conditionally preferred over TMP/SMX for remission maintenance. \n\nTrimethoprim/sulfamethoxazole may have a role in patients with sinonasal involvement, but overall it is not recommended as a primary agent for remission maintenance in GPA/MPA.",
        "contexto": [
            "|Recommendation: In patients with GPA whose disease has entered remission, we conditionally recommend against adding trimethoprim/sulfamethoxazole to other therapies (e.g., rituximab, azathioprine, methotrexate, etc.) for the purpose of remission maintenance.|23|Low to moderate|",
            "disease has entered remission, we conditionally recommend against adding trimethoprim/sulfamethoxazole to other therapies (e.g., rituximab, azathioprine, methotrexate, etc.) for the purpose of remission maintenance. Trimethoprim/sulfamethoxazole may have benefit for patients with sinonasal involvement Recommendation: For patients with GPA/MPA receiving remission maintenance therapy with rituximab who have hypogammaglobulinemia (e.g., IgG <3 gm/liter) and recurrent severe infections, we",
            "|Recommendation: For patients with GPA whose disease has entered remission, we conditionally recommend treatment with methotrexate or azathioprine over trimethoprim/sulfamethoxazole for remission maintenance.|21, 22|Very low to low|",
            "we conditionally recommend treatment with methotrexate or azathioprine over trimethoprim/sulfamethoxazole for remission maintenance. The Voting Panel strongly favored the use of methotrexate or azathioprine over trimethoprim/sulfamethoxazole, but this recommendation is conditional due to the lack of sufficient high-quality evidence comparing the 2 treatments. Recommendation: In patients with GPA whose disease has entered remission, we conditionally recommend against adding",
            "and glucocorticoids. Methotrexate is considered more effective than trimethoprim/sulfamethoxazole for remission induction, based on previous findings Remission maintenance Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally recommend treatment with rituximab over methotrexate or azathioprine for remission maintenance. Rituximab is associated with a lower relapse rate than azathioprine when used"
        ]
    },
    {
        "pregunta": "10. What are the recommended rituximab dosing schedules for remission maintenance therapy in adults and children?",
        "respuesta": "The recommended rituximab dosing schedules for remission maintenance therapy are:\n\n- **Adults:** 500 mg IV every 6 months or 1,000 mg IV every 4 months.\n- **Children:** 250 mg/m² IV every 6 months.\n\nOther dosing regimens may be used but these are the primary schedules noted.",
        "contexto": [
            "|Rituximab|375 mg/m² (IV) weekly for 4 doses or 1,000 mg on days 1 and 15 (adults); or 375 mg/m² (IV) weekly for 4 doses or 575 mg/m² for patients with body surface area ≤1.5m or 750 mg/m² for patients with body surface area &gt;1.5m² with a typical maximum of 1 gm per infusion (both for 2 doses, days 1 and 15) (children)|\n|Mepolizumab|300 mg (SC) every 4 weeks (adults)|\n|Remission maintenance therapy| |",
            "|Remission maintenance therapy| |\n|Methotrexate, azathioprine, mycophenolate mofetil|Same dosing regimen as in remission induction therapy|\n|Rituximab|500 mg (IV) every 6 months or 1 gm (IV) every 4 months (adults), 250 mg/m² (IV) every 6 months (children), or other doses|\n|Mepolizumab|300 mg (SC) every 4 weeks|\n|Omalizumab|300–600 mg (SC) every 2–4 weeks|</p>",
            "is associated with a lower relapse rate than azathioprine when used for remission maintenance after remission induction with cyclophosphamide Different doses of rituximab have been used for remission maintenance, including IV 500 mg every 6 months  (FDA-approved), IV 1,000 mg every 4 months If methotrexate or azathioprine treatment is being considered for remission maintenance, the patient's clinical situation, preferences, and values should guide selection between them, given their comparable",
            "|Recommendation: For patients with GPA/MPA who are receiving rituximab for remission maintenance, we conditionally recommend scheduled re-dosing over using ANCA titers or CD19+ B cell counts to guide re-dosing.|24, 25|Very low to low|",
            "and values should guide selection between them, given their comparable efficacy. Recommendation: For patients with GPA/MPA who are receiving rituximab for remission maintenance, we conditionally recommend scheduled re-dosing over using ANCA titers or CD19+ B cell counts to guide re-dosing. In one randomized trial, patients who received rituximab for remission maintenance based on changes in CD19+ B cell counts and/or ANCA titers had similar rates of relapse as those receiving rituximab as a"
        ]
    },
    {
        "pregunta": "11. Why is mepolizumab not recommended for remission induction in active, severe EGPA?",
        "respuesta": "Mepolizumab is not recommended for remission induction in patients with active, severe eosinophilic granulomatosis with polyangiitis (EGPA) because its efficacy in this population has not been established. Patients with active, severe EGPA were excluded from the randomized trial that demonstrated mepolizumab's benefit, and thus, current guidelines conditionally recommend using cyclophosphamide or rituximab over mepolizumab for remission induction in severe disease.",
        "contexto": [
            "in other forms of vasculitis Recommendation: For patients with active, severe EGPA, we conditionally recommend treatment with cyclo phosphamide or rituximab over mepolizumab for remission induction. The efficacy of mepolizumab in severe EGPA has not been established, as patients with active, severe disease were excluded from the randomized trial Remission induction for active, nonsevere disease Recommendation: For patients with active, nonsevere EGPA, we conditionally recommend initiating",
            "be maximized prior to increasing systemic immunosuppressive therapy. Although no direct comparative data are available, mepolizumab was found to be efficacious in a randomized trial in patients specifically described in this recommendation: those with relapsing nonsevere EGPA who are receiving immunosuppressive therapy Recommendation: For patients with EGPA who have experienced relapse with nonsevere disease manifestations (asthma and/or sinonasal disease) while receiving low-dose",
            "|Recommendation: For patients with EGPA who have experienced relapse with nonsevere disease manifestations (asthma and/or sinonasal disease) while receiving methotrexate, azathioprine, or mycophenolate mofetil, we conditionally recommend adding mepolizumab over switching to another agent.|26|Very low|",
            "|Recommendation: For patients with active, severe EGPA, we conditionally recommend treatment with cyclophosphamide or rituximab over mepolizumab for remission induction.|6, 7|Low|\n|Remission induction for active, nonsevere disease| | |\n|Recommendation: For patients with active, nonsevere EGPA, we conditionally recommend initiating treatment with mepolizumab and GCs over methotrexate, azathioprine, or mycophenolate mofetil and GCs.|8, 9, 10, 13|Very low to low|",
            "(see ungraded position statement and recommendation on this topic). Recommendation: For patients with EGPA who have experienced relapse with nonsevere disease manifestations (asthma and/or sinonasal disease) while receiving methotrexate, azathioprine, or mycophenolate mofetil, we conditionally recommend adding mepolizumab over switching to another agent. For patients with EGPA with active asthma, inhaled therapies should be maximized prior to increasing systemic immunosuppressive therapy."
        ]
    },
    {
        "pregunta": "12. Which agents are recommended for remission induction therapy in severe active GPA or MPA, and what is the conditional recommendation between rituximab and cyclophosphamide?",
        "respuesta": "For remission induction therapy in patients with active, severe granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), the guideline conditionally recommends treatment with **rituximab over cyclophosphamide**. Both agents, when combined with glucocorticoids, have demonstrated similar efficacy for remission induction; however, rituximab is preferred based on available evidence. \n\nIn cases of treatment-refractory severe GPA/MPA (i.e., disease not responding to either rituximab or cyclophosphamide), the guideline conditionally recommends switching to the alternate agent rather than combining the two. \n\nThus, rituximab is preferred as first-line remission induction therapy but cyclophosphamide remains a valid alternative depending on clinical context.",
        "contexto": [
            "abstract Table 1 2 1 Remission induction for active, severe disease Recommendation: For patients with active, severe GPA/MPA, we conditionally recommend treatment with rituximab over cyclophosphamide for remission induction. Both rituximab and cyclophosphamide, in combination with glucocorticoids, have been used for remission induction in GPA and MPA. Rituximab has been shown to provide similar benefits to cyclophosphamide for remission induction in a randomized controlled trial",
            "Recommendation: For patients with severe GPA/MPA that is refractory to treatment with rituximab or cyclophosphamide for remission induction, we conditionally recommend switching treatment to the other therapy over combining the 2 therapies. Disease refractory to remission induction therapy is rare, and there are limited data to guide treatment recommendations. Practitioners should evaluate whether other conditions such as infection could be mimicking vasculitis. However, if a patient's disease",
            "<p>|Recommendation/statement|PICO question informing recommendation and discussion|Level of evidence|\n|---|---|---|\n|Remission induction for active, severe disease| | |\n|Recommendation: For patients with active, severe GPA/MPA, we conditionally recommend treatment with rituximab over cyclophosphamide for remission induction.|4, 5, 6|Very low to moderate|",
            "|Recommendation: For patients with severe GPA/MPA whose disease has entered remission after treatment with cyclophosphamide or rituximab, we conditionally recommend treatment with methotrexate or azathioprine over mycophenolate mofetil for remission maintenance.|19|Very low to moderate|",
            "|Treatment of refractory disease| | |\n|Recommendation: For patients with severe GPA/MPA that is refractory to treatment with rituximab or cyclophosphamide for remission induction, we conditionally recommend switching treatment to the other therapy over combining the 2 therapies.|30|Very low|</p>"
        ]
    },
    {
        "pregunta": "13. According to the guideline, why should treatment recommendations not be used to restrict access to therapies?",
        "respuesta": "According to the guideline, treatment recommendations should not be used by any agency to restrict access to therapies or to require that certain therapies be utilized prior to others because all recommendations are conditional and meant to guide treatment for the typical patient. They acknowledge that evidence is often limited or uncertain, and alternative therapies may be appropriate depending on individual patient circumstances, comorbidities, and patient preferences. Thus, application of recommendations must be individualized, requiring clinical judgment and shared decision-making, and should not limit patient access to potentially beneficial treatments.",
        "contexto": [
            "convey that, although the suggested course of action will be best for many patients, there will be some patients in whom, considering their comorbidities and/or their values and preferences, the alternative represents the best choice. The guideline will be updated as new evidence from comparative studies becomes available. A Patient Panel meeting was held prior to the Voting Panel meeting to gain insight into patients' values and preferences for the pharmacologic/nonpharmacologic intervention",
            "by a greater number of randomized trials than are currently available in EGPA. All of the recommendations made for these 3 diseases are conditional, which indicates that there are settings in which the evidence is not strong or an alternative is a reasonable consideration. These recommendations should not be used by any agency to restrict access to therapy or require that certain therapies be utilized prior to other therapies. The physicians on the Voting Panel were primarily rheumatologists,",
            "Recommendations are meant to describe the approach to treatment of the typical patient and cannot anticipate all possible clinical scenarios. Application of these recommendations must be individualized, and requires careful assessment, sound clinical judgment of each patient's circumstances, and consideration of a patient's preferences.    The views expressed herein do not necessarily represent those of the National Institutes of Health United States Department of Veterans Affairs American",
            "of moderate-or high-quality rating of the evidence, and a conditional recommendation in the presence of very-low or low-quality evidence (although recommendations can also be conditional in the setting of moderate-quality evidence, and in certain circumstances strong in the face of low-quality evidence) Limitations of the guideline include the limited comparative evidence to inform selection of therapies (i.e., primary comparative benefit/efficacy and harms evidence) and the inability to",
            "therapy is no longer helpful; however, absence of their perspective is recognized as a limitation. Also, our population is those patients who have attempted nonoperative treatment and for whom that treatment is no longer effective. The determination that a treatment is no longer effective is individualized as determined by a shared decision-making process between a patient and the physician. We did not include patients who have rheumatoid arthritis (RA) in this guideline, which is a limitation"
        ]
    },
    {
        "pregunta": "14. How should glucocorticoid dosing be managed in EGPA to balance disease control and toxicity?",
        "respuesta": "In patients with eosinophilic granulomatosis with polyangiitis (EGPA), glucocorticoid dosing should be individualized to balance effective disease control and minimize toxicity. Key points include:\n\n- Use intravenous pulse glucocorticoids or high-dose oral glucocorticoids as initial therapy in active, severe EGPA; neither approach is favored over the other based on current data.\n- Combine glucocorticoids with a nonglucocorticoid immunosuppressive agent such as cyclophosphamide in severe disease.\n- After induction, prescribe the minimum effective glucocorticoid dose to maintain disease quiescence, particularly to control asthma and allergy symptoms.\n- Many patients may require low-dose glucocorticoids long-term to maintain control.\n- Screening for glucocorticoid toxicities (e.g., osteoporosis) should be conducted.\n- Treatment duration should be guided by the patient’s clinical condition, values, and preferences, as no specific duration is supported by current evidence.\n\nThus, glucocorticoid therapy in EGPA should be carefully tapered to the lowest effective dose to reduce toxicity while maintaining disease control.",
        "contexto": [
            "position statement: The duration of glucocorticoid therapy in EGPA should be guided by the patient's clinical condition, values, and preferences. There is insufficient published evidence to support a specific duration of glucocorticoid treatment, and thus, the length of glucocorticoid therapy should be determined based on each patient's clinical circumstances. Many patients with EGPA require some treatment with glucocorticoids, generally at a low dose, to maintain control of asthma and allergy",
            "generally at a low dose, to maintain control of asthma and allergy symptoms. The minimum effective dose should be prescribed to minimize glucocorticoid toxicity. Treatment of disease relapse Recommendation: For patients with EGPA who have experienced relapse with severe disease manifestations after prior successful remission induction with cyclophosphamide, we conditionally recommend treatment with rituximab over cyclophosphamide for remission re-induction. Rituximab is favored based on the",
            "position statement: For patients with active, severe EGPA, either IV pulse glucocorticoids or high-dose oral glucocorticoids may be prescribed as initial therapy. There are no data to support favoring either IV pulse or highdose oral glucocorticoids over the other option in active, severe EGPA. Choosing an approach should be influenced by individual patient factors. In either instance, glucocorticoids should be combined with a nonglucocorticoid immunosuppressive agent such as cyclophosphamide",
            "<h1>Key recommendations for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA)</h1>",
            "associated with its use. Overall, patients expressed a desire to minimize the glucocorticoid dose as much as possible but recognized that some patients may require low-dose glucocorticoids long-term to maintain disease quiescence. Screening for toxicities of glucocorticoid use (e.g., bone mineral density testing for osteoporosis) should be conducted. Treatment of disease relapse Recommendation: For patients with GPA/MPA who have experienced relapse with severe disease manifestations and are not"
        ]
    },
    {
        "pregunta": "15. What is the conditional recommendation for treating relapse with severe disease manifestations in EGPA after prior cyclophosphamide therapy?",
        "respuesta": "For patients with eosinophilic granulomatosis with polyangiitis (EGPA) who have experienced relapse with severe disease manifestations after prior successful remission induction with cyclophosphamide, the guideline conditionally recommends treatment with **rituximab over cyclophosphamide** for remission re-induction.",
        "contexto": [
            "|Treatment of relapse| | |\n|Recommendation: For patients with EGPA who have experienced relapse with severe disease manifestations after prior successful remission induction with cyclophosphamide, we conditionally recommend treatment with rituximab over cyclophosphamide for remission re-induction.|25|Very low|",
            "<h1>Key recommendations for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA)</h1>",
            "|Recommendation: For patients with EGPA who have experienced relapse with severe disease manifestations after prior successful remission induction with rituximab, we conditionally recommend treatment with rituximab over switching to cyclophosphamide for remission re-induction.|25|Very low|",
            "|Recommendation: For patients with active, severe EGPA, we conditionally recommend treatment with cyclophosphamide or rituximab over mepolizumab for remission induction.|6, 7|Low|\n|Remission induction for active, nonsevere disease| | |\n|Recommendation: For patients with active, nonsevere EGPA, we conditionally recommend initiating treatment with mepolizumab and GCs over methotrexate, azathioprine, or mycophenolate mofetil and GCs.|8, 9, 10, 13|Very low to low|",
            "|Recommendation: For patients with EGPA who have experienced relapse with nonsevere disease manifestations (asthma and/or sinonasal disease) while receiving low-dose GCs and no other therapy, we conditionally recommend adding mepolizumab over adding methotrexate, azathioprine, or mycophenolate mofetil.|28|Very low|"
        ]
    },
    {
        "pregunta": "16. What are the primary diseases included under ANCA-associated vasculitis (AAV) according to the guideline?",
        "respuesta": "According to the guideline, the primary diseases included under ANCA-associated vasculitis (AAV) are:\n\n- Granulomatosis with polyangiitis (GPA)  \n- Microscopic polyangiitis (MPA)  \n- Eosinophilic granulomatosis with polyangiitis (EGPA)",
        "contexto": [
            "2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis  unknown      A7FDDF976624E2E85584FDD8C00804F0 10.1002/acr.24634  INTRODUCTION The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) comprise granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). These diseases affect smalland medium-sized vessels",
            "vasculitis</strong><br><strong>Relapsing polychondritis</strong><br><strong>Behçet's disease</strong><br><strong>Kawasaki disease</strong><br><strong>IgA vasculitis (Henoch-Schönlein)</strong><br><strong>Primary CNS vasculitis</strong><br><strong>Goodpasture's syndrome (anti-GBM)</strong><br><strong>Cogan's syndrome</strong><br><strong>Cutaneous small vessel vasculitis</strong><br><strong>Rheumatoid vasculitis</strong><br><strong>Urticarial vasculitis</strong> |",
            "polyangiitis (EGPA). These diseases affect smalland medium-sized vessels and are characterized by multisystem organ involvement. GPA is characterized histologically by necrotizing granulomatous inflammation in addition to vasculitis. Common clinical manifestations include destructive sinonasal lesions, pulmonary nodules, and pauci-immune glomerulonephritis. GPA is most commonly associated with cytoplasmic ANCA and antibodies to proteinase 3 (PR3). Among European populations, prevalence ranges",
            "populations has been estimated to range from 2 to 38 cases per million Prior to the use of alkylating agents, survival with these diseases was quite poor (e.g., median survival of patients with GPA was ~5 months) The Voting Panel was assembled for the ACR and Vasculitis Foundation's broad effort to develop recommendations for 7 forms of systemic vasculitis: giant cell arteritis, Takayasu arteritis, polyarteritis nodosa, Kawasaki syndrome, and the 3 AAVs presented in this report. The physicians",
            "undifferentiated connective tissue disease, ankylosing spondylitis, antineutrophil cytoplasmic antibody-associated vasculitis, systemic lupus erythematosus (SLE), or unclassifiable ILD. There was a need to limit the guideline scope, so the five diseases in which ILD occurs most frequently were prioritized. IPAF was not included because it is a research classification rather than a clinical diagnosis. Also, this guideline was not developed to guide evaluation for SARDs in patients with newly"
        ]
    },
    {
        "pregunta": "17. Under what circumstances might plasma exchange be used as a “salvage” or “rescue” therapy in GPA/MPA?",
        "respuesta": "Plasma exchange may be used as a “salvage” or “rescue” therapy in patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) who are at higher risk of progression to end-stage renal disease (ESRD). Additionally, plasma exchange remains advisable in patients with GPA or MPA who also have anti-glomerular basement membrane (anti-GBM) disease.\n\nRoutine use of plasma exchange is **not** recommended in active glomerulonephritis or in active, severe disease with alveolar hemorrhage, but it can be considered selectively as salvage therapy in the above contexts.",
        "contexto": [
            "induction therapies (i.e., plasma exchange as \"salvage\" or \"rescue\" therapy). Plasma exchange remains advisable in patients with GPA or MPA who also have anti-glomerular basement membrane disease. Ungraded position statement: For patients with active, severe GPA/MPA, either IV pulse glucocorticoids or high-dose oral glucocorticoids may be prescribed as part of initial therapy. There are no trials comparing the efficacy of IV pulse glucocorticoids to high-dose oral glucocorticoids. Higher doses",
            "venous thrombotic events.  Plasma exchange remains advisable in patients with GPA or MPA who also have anti-glomerular basement membrane disease. Recommendation: In patients with active, severe GPA/MPA with alveolar hemorrhage, we conditionally recommend against adding plasma exchange to remission induction therapies. Two trials evaluated the use of plasma exchange in patients presenting with alveolar hemorrhage, and no differences in mortality or remission rates were observed. Thus, plasma",
            "|Recommendation: In patients with GPA/MPA with active glomerulonephritis, we conditionally recommend against the routine addition of plasma exchange to remission induction therapy.|34|Low to high|\n|Recommendation: In patients with active, severe GPA/MPA with alveolar hemorrhage, we conditionally recommend against adding plasma exchange to remission induction therapies.|35|Low to high|",
            "For patients with GPA/MPA in remission and stage 5 chronic kidney disease, we conditionally recommend evaluation for renal transplantation. Low Recommendation: For patients with active GPA/MPA who are unable to receive other immunomodulatory therapy, we conditionally recommend administering IVIG. Low Ungraded position statement: The optimal duration of anticoagulation is unknown for patients with GPA/MPA who experience venous thrombotic events.  Plasma exchange remains advisable in patients",
            "cyclophosphamide for remission induction in a randomized controlled trial Cyclophosphamide (dosing provided in Table 1 Recommendation: In patients with GPA/MPA with active glomerulonephritis, we conditionally recommend against the routine addition of plasma exchange to remission induction therapy. Plasma exchange should not be initiated in all patients with active glomerulonephritis but can be considered for patients at higher risk of progression to end-stage renal disease (ESRD) who accept a"
        ]
    },
    {
        "pregunta": "18. Under what conditions is reconstructive surgery recommended for patients with GPA who have nasal septal defects or nasal bridge collapse?",
        "respuesta": "For patients with granulomatosis with polyangiitis (GPA) who have nasal septal defects and/or nasal bridge collapse, reconstructive surgery is **conditionally recommended** if desired by the patient. To optimize surgical outcomes, such reconstructive surgery should be performed after a period of sustained remission by an otolaryngologist with expertise in treating GPA.",
        "contexto": [
            "| |Recommendation: For patients with GPA in remission who have nasal septal defects and/or nasal bridge collapse, we conditionally recommend reconstructive surgery, if desired by the patient.|Low|\n| |Recommendation: For patients with GPA and actively inflamed subglottic and/or endobronchial tissue with stenosis, we conditionally recommend treating with immunosuppressive therapy over surgical dilation with intralesional GC injection alone.|Low|",
            "For patients with sinonasal involvement in GPA, nasal rinses and topical nasal therapies (antibiotics, lubricants, and GCs) may be beneficial. 36, 37, 38, 39 Very low to low Recommendation: For patients with GPA in remission who have nasal septal defects and/or nasal bridge collapse, we conditionally recommend reconstructive surgery, if desired by the patient. Low Recommendation: For patients with GPA and actively inflamed subglottic and/or endobronchial tissue with stenosis, we conditionally",
            "sinonasal involvement in GPA, nasal rinses and topical nasal therapies (antibiotics, lubricants, and glucocorticoids) may be beneficial. We suggest collaborating with an otolaryngologist with expertise in treating GPA to determine whether these interventions should be used. Recommendation: For patients with GPA in remission who have nasal septal defects and/or nasal bridge collapse, we conditionally recommend reconstructive surgery, if desired by the patient. To optimize surgical outcomes,",
            "surgery, if desired by the patient. To optimize surgical outcomes, reconstructive surgery should be performed, after a period of sustained remission, by an otolaryngologist with expertise in treating GPA Recommendation: For patients with GPA and actively inflamed subglottic and/or endobronchial tissue with stenosis, we conditionally recommend treating with immunosuppressive therapy over surgical dilation with intralesional glucocorticoid injection alone. Subglottic or endobronchial stenoses",
            "that could influence whether plasma exchange is initiated include the patient's kidney function upon presentation, rate of loss of kidney function, response to remission induction therapies, and the patient's ability to tolerate serious infections. Recommendation/statement PICO question informing recommendation and discussion Level of evidence Treatment of sinonasal, airway, and mass lesions Ungraded position statement: For patients with sinonasal involvement in GPA, nasal rinses and topical"
        ]
    },
    {
        "pregunta": "19. What prophylactic measures are recommended to prevent Pneumocystis jirovecii pneumonia in patients with GPA/MPA receiving rituximab or cyclophosphamide?",
        "respuesta": "For patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) who are receiving rituximab or cyclophosphamide, the guideline conditionally recommends prescribing prophylactic medications to prevent Pneumocystis jirovecii pneumonia (PJP). This prophylaxis is routinely used, especially with cyclophosphamide therapy, to reduce the risk of this opportunistic infection.",
        "contexto": [
            "| |Recommendation: For patients with GPA who are receiving rituximab or cyclophosphamide, we conditionally recommend prophylaxis to prevent Pneumocystis jiroveci pneumonia.|Low|\n| |Recommendation: For patients with GPA/MPA in remission and stage 5 chronic kidney disease, we conditionally recommend evaluation for renal transplantation.|Low|",
            "recommend prescribing medications for prophylaxis to prevent P jirovecii pneumonia. Prophylaxis to prevent P jirovecii pneumonia is discussed above in the GPA/MPA recommendations. The same considerations regarding prophylaxis to prevent this condition in patients with GPA/MPA apply to those with EGPA. DISCUSSION In this guideline, we present the first ACR/Vasculitis Foundation recommendations for the management of GPA, MPA, and EGPA. Although these recommendations provide a general guide for",
            "we conditionally recommend prescribing medications for prophylaxis to prevent Pneumocystis jirovecii pneumonia. | 1099 is less commonly used in younger children receiving rituximab but should be considered. Recommendation: For patients with GPA/MPA in remission and stage 5 chronic kidney disease, we conditionally recommend evaluation for renal transplantation. Outcomes of kidney transplantation in patients with AAV are similar to those in patients receiving transplants for other reasons, with",
            "|Recommendation: For patients with EGPA who are receiving cyclophosphamide or rituximab, we conditionally recommend prescribing medications for prophylaxis to prevent Pneumocystis jiroveci pneumonia.|32|Low|</p>",
            "recommend against dosing immunosuppressive therapy based on ANCA titer results alone. Increases in ANCA titers/levels are only modestly informative as an indicator of disease activity Recommendation: For patients with GPA/MPA who are receiving rituximab or cyclophosphamide, we conditionally recommend prophy laxis to prevent P jirovecii pneumonia. Prophylaxis to prevent P jirovecii pneumonia is routinely used with cyclophosphamide treatment Very low Recommendation: For patients with EGPA, we"
        ]
    },
    {
        "pregunta": "20. How does the timing since the last rituximab infusion influence the choice between rituximab and cyclophosphamide for remission re-induction in GPA/MPA?",
        "respuesta": "The timing since the last rituximab infusion influences the choice of agent for remission re-induction in GPA/MPA as follows:\n\n- If an extended period has passed since the last rituximab infusion, a remission induction dose of rituximab may be effective for re-induction.\n- If the patient recently received rituximab, cyclophosphamide is recommended for remission re-induction.\n\nIn both scenarios, these agents should be used in conjunction with glucocorticoids. Thus, the recency of the last rituximab dose guides whether to repeat rituximab or switch to cyclophosphamide for remission re-induction.",
        "contexto": [
            "time since last rituximab infusion and cumulative cyclophosphamide dose. Cyclophosphamide is recommended if the patient recently received rituximab, while a remission induction dose of rituximab may be | 1097 effective if an extended period has passed since the last rituximab infusion. As is standard for remission induction, these agents should be used in conjunction with glucocorticoids. Treatment of refractory disease Recommendation: For patients with severe GPA/MPA that is refractory to",
            "randomized controlled trial Recommendation: For patients with GPA/MPA who experienced relapse with severe disease manifestations while receiving rituximab for remission maintenance, we conditionally recommend switching from rituximab to cyclophosphamide over receiving additional rituximab for remission re-induction. Multiple factors can influence whether rituximab or cyclophosphamide treatment (IV or oral) is used, such as time since last rituximab infusion and cumulative cyclophosphamide dose.",
            "abstract Table 1 2 1 Remission induction for active, severe disease Recommendation: For patients with active, severe GPA/MPA, we conditionally recommend treatment with rituximab over cyclophosphamide for remission induction. Both rituximab and cyclophosphamide, in combination with glucocorticoids, have been used for remission induction in GPA and MPA. Rituximab has been shown to provide similar benefits to cyclophosphamide for remission induction in a randomized controlled trial",
            "have experienced relapse with severe disease manifestations and are not receiving rituximab for remission maintenance, we conditionally recommend treatment with rituximab over cyclophosphamide for remission re-induction. Rituximab is more effective than oral cyclophosphamide for reinduction of remission among patients who previously received cyclophosphamide and then experienced relapse, based on subgroup analysis of a randomized controlled trial Recommendation: For patients with GPA/MPA who",
            "|Recommendation: For patients with GPA/MPA who experienced relapse with severe disease manifestations while receiving rituximab for remission maintenance, we conditionally recommend switching from rituximab to cyclophosphamide over receiving additional rituximab for remission re-induction.|29|Very low|\n|Treatment of refractory disease| | |"
        ]
    }
]